Loading...

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin

Saxagliptin is a novel dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) for the treatment of type 2 diabetes, with a duration profile for once daily dosing. It is highly selective for DPP-4 in comparison to other enzymes of the dipeptidyl peptidase family. DPP-4 inhibitors elevate plasma concentra...

Full description

Saved in:
Bibliographic Details
Main Author: Gallwitz, Baptist
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2010
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3047961/
https://ncbi.nlm.nih.gov/pubmed/21437082
Tags: Add Tag
No Tags, Be the first to tag this record!